A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes

Neurology

Volumn 47, Issue 2, 1996, Pages 544-546

  Scoles, Daniel R ^a   Baser, Michael E ^a   Pulst, Stefan M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLALANINE; SERINE;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MISSENSE MUTATION; NEUROFIBROMATOSIS; PHENOTYPE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0029831658     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.2.544     Document Type: Article

References (14)

1. Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992;29:841-846.
2. Mautner VF, Lindenau M, Baser M, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880-886.
3. Merel P, Hoang-Xuan K, Sanson M, et al. Screening for germline mutations in the NF2 gene. Genes Chrom Cancer 1995; 12:117-127.
4. Bourn D, Carter SA, Mason S, Evans DGR, Strachan T. Germline mutations in the neurofibromatosis type 2 tumor suppressor gene. Hum Mol Genet 1994;3:813-816.
5. Sainz J, Huynh DP, Figueroa K, Ragge NK, Baser ME, Pulst S-M. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet 1994;3:885-891.
6. Jacoby LB, MacCollin M, Louis DM, et al. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet 1994;3:413-419.
7. MacCollin M, Mohney T, Trofatter J, Wertelecki W, Ramesh V, Gusella J. DNA diagnosis of neurofibromatosis 2. JAMA 1993;270:2316-2330.
8. Evans DGR, Bourn D, Wallace A, Ramaden RT, Mitchell JD, Strachan T. Diagnostic issues in a family with late onset type 2 neurofibromatosis. J Med Genet 1995;32:470-474.
9. Kluwe L, Mautner V-F. A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. Hum Genet 1996;97:224-227.
10. Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Maher ER. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma. Hum Mol Genet 1994;3:347-350.
11. Bianchi AB, Hara T, Ramesh V, et al. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet 1994;6:185-192.
12. Bourn D, Carter SA, Evans DGR, Goodship J, Coakham H, Strachan T. A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet 1994;55:69-73.
13. Kluwe L, Pulst SM, Köppen J, Mautner V-F. A 163-bp deletion at the C-terminus of the schwannomin gene associated with variable phenotypes of neurofibromatosis type 2. Hum Genet 1995;4:443-446.
14. Baser ME, Ragge NK, Riccardi VM, Ganz B, Janus T, Pulst S-M. Phenotypic variability in monozygotic twins with neurofibromatosis 2. Am J Med Genet (In press).